DE69526937T2 - Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen - Google Patents

Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen

Info

Publication number
DE69526937T2
DE69526937T2 DE69526937T DE69526937T DE69526937T2 DE 69526937 T2 DE69526937 T2 DE 69526937T2 DE 69526937 T DE69526937 T DE 69526937T DE 69526937 T DE69526937 T DE 69526937T DE 69526937 T2 DE69526937 T2 DE 69526937T2
Authority
DE
Germany
Prior art keywords
pct
acid derivatives
methanbisphosphonic
lossed
prostheses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69526937T
Other languages
English (en)
Other versions
DE69526937D1 (de
Inventor
Allen E Goodship
John Kenwright
Jonathan Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Erfindungen Verwaltungs GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfindungen Verwaltungs GmbH, Novartis AG filed Critical Novartis Erfindungen Verwaltungs GmbH
Publication of DE69526937D1 publication Critical patent/DE69526937D1/de
Application granted granted Critical
Publication of DE69526937T2 publication Critical patent/DE69526937T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Dental Preparations (AREA)
DE69526937T 1994-05-04 1995-04-24 Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen Expired - Fee Related DE69526937T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9408775A GB9408775D0 (en) 1994-05-04 1994-05-04 Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
PCT/IB1995/000288 WO1995030421A1 (en) 1994-05-04 1995-04-24 Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration

Publications (2)

Publication Number Publication Date
DE69526937D1 DE69526937D1 (de) 2002-07-11
DE69526937T2 true DE69526937T2 (de) 2003-01-02

Family

ID=10754497

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69526937T Expired - Fee Related DE69526937T2 (de) 1994-05-04 1995-04-24 Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen

Country Status (18)

Country Link
US (1) US5965547A (de)
EP (1) EP0758241B1 (de)
JP (1) JPH09512816A (de)
AT (1) ATE218350T1 (de)
AU (1) AU693541B2 (de)
DE (1) DE69526937T2 (de)
DK (1) DK0758241T3 (de)
ES (1) ES2177642T3 (de)
FI (1) FI118590B (de)
GB (1) GB9408775D0 (de)
HU (1) HUT74984A (de)
IL (1) IL113566A (de)
NO (1) NO310057B1 (de)
NZ (1) NZ283430A (de)
PT (1) PT758241E (de)
TW (1) TW458779B (de)
WO (1) WO1995030421A1 (de)
ZA (1) ZA953537B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
GB2336311A (en) * 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
US6137012A (en) 1998-10-13 2000-10-24 E. I. Du Pont De Nemours And Company Phosphole and diphosphole ligands for catalysis
TR200101546T2 (tr) * 1998-12-04 2001-11-21 Roche Diagnostics Gmbh İç-protezlerde kemik entegrasyonunu iyileştirmek üzere ibandronat kullanılması.
JP2002536123A (ja) * 1999-02-09 2002-10-29 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 抗吸収性骨セメントならびに同種、自家、および異種骨移植片
US6692758B1 (en) * 1999-08-02 2004-02-17 Toray Industries, Inc. Insertion stabilizers for implants
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
ES2394211T3 (es) * 2000-06-20 2013-01-23 Novartis Ag Procedimiento de administración de bifosfonatos
SI1591122T1 (sl) 2000-06-20 2013-02-28 Novartis Ag Postopek za aplikacijo bisfosfonatov
WO2002004038A1 (en) * 2000-07-12 2002-01-17 Hopital Orthopedique De La Suisse Romande Active biocoating for bone implant
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
WO2003095029A1 (en) * 2002-05-10 2003-11-20 F. Hoffmann-La Roche Ag Bisphosphonic acid for the treatment and prevention of osteoporosis
WO2004024166A1 (en) * 2002-09-16 2004-03-25 Novartis Ag Method for preventing or reducing secondary fractures after hip fracture
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
AR064262A1 (es) * 2006-11-17 2009-03-25 Besins Healthcare Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato
EP1958649A1 (de) * 2007-02-14 2008-08-20 Graftys Injizierbarer Kalzium-Phospat-Zement zur Freisetzung eines Knochenschwund-Inhibitors
EP2136814A4 (de) * 2007-03-21 2012-05-30 Univ Duke Medikationskits und formulierungen zur verhütung, behandlung oder reduzierung von sekundären frakturen nach einer vorhergehenden fraktur
US20100317859A1 (en) * 2007-05-16 2010-12-16 Actavis Group Ptc Ehf Process for the Preparation of Risedronate Sodium
CN102639137A (zh) 2009-09-01 2012-08-15 杜克大学 双膦酸类组合物及其治疗心力衰竭的方法
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
WO2013074587A1 (en) 2011-11-16 2013-05-23 Duke University Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3776880D1 (de) * 1986-11-21 1992-04-02 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
JPH05163150A (ja) * 1991-05-13 1993-06-29 E R Squibb & Sons Inc アテローム性動脈硬化症の抑制・治療剤
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices

Also Published As

Publication number Publication date
EP0758241B1 (de) 2002-06-05
FI118590B (fi) 2008-01-15
TW458779B (en) 2001-10-11
DE69526937D1 (de) 2002-07-11
AU2146695A (en) 1995-11-29
ATE218350T1 (de) 2002-06-15
IL113566A0 (en) 1995-08-31
DK0758241T3 (da) 2002-09-23
EP0758241A1 (de) 1997-02-19
ES2177642T3 (es) 2002-12-16
PT758241E (pt) 2002-10-31
NO964486D0 (no) 1996-10-22
NZ283430A (en) 2000-06-23
NO310057B1 (no) 2001-05-14
HU9603042D0 (en) 1997-01-28
FI964332A0 (fi) 1996-10-28
WO1995030421A1 (en) 1995-11-16
NO964486L (no) 1996-10-22
ZA953537B (en) 1995-11-06
IL113566A (en) 2002-05-23
HUT74984A (en) 1997-03-28
FI964332A (fi) 1996-10-28
US5965547A (en) 1999-10-12
JPH09512816A (ja) 1997-12-22
AU693541B2 (en) 1998-07-02
GB9408775D0 (en) 1994-06-22

Similar Documents

Publication Publication Date Title
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE69317578T2 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
DE69616376T2 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
ATE222488T1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
DE59508961D1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
DE69634404D1 (de) Caroteinoid-nicotinamid-zink zusammensetzungen und verfahren zur behandlung unter verwendung derselben
BG105275A (en) Tan-1057 derivatives
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE59107536D1 (de) Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
DE69525631T2 (de) Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE69124382T3 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
ATE312611T1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
MX9605327A (es) Uso de ciertos derivados de acido metanbisfosfonico para prevenir el aflojamiento de las protesis y la emigracion de las protesis.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8339 Ceased/non-payment of the annual fee